5,000 kidney patients enrolled in landmark registry study

NCT ID NCT06117852

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study is creating a registry of 5,000 adults with chronic kidney disease (CKD) to collect information on their health, treatments, and outcomes. Researchers aim to understand how the disease progresses, identify risk factors, and see how well current treatments match guidelines. No new treatments are being tested—this is purely an observation and data-gathering effort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this registry could help doctors better predict how chronic kidney disease will progress and improve treatment guidelines.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help participants. Results may take years and might not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

CKD patients with age not less than 18 years old.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Registry Platform Study Basic Inclusion \& Exclusion Criteria: Inclusion Criteria: 1. Aged ≥ 18 years at enrollment; 2. Patients who meet the diagnostic criteria for CKD; 3. Last eGFR ≥ 20 and \< 90 mL/min/1.73 m2 (with the CKD-EPI formula) within 12 months prior to enrollment; 4. Patients who voluntarily participate in this study and has signed and dated the informed consent form for the study; Exclusion Criteria: 1. Patients who have previously undergone/are undergoing/are planning to undergo solid organ transplantation; 2. Patients with active malignant tumor requiring drug therapy at the time of screening; 3. Women who are pregnant, planning to become pregnant or who are breastfeeding. Group A (Participants with CKD and High Proteinuria) Inclusion \& Exclusion Criteria: Inclusion criteria: Last documented proteinuria test within 12 months prior to enrollment indicating UACR ≥ 700 mg/g, or UPCR ≥ 1000 mg/g, or 24 h urine protein (quantitative) ≥ 1 g/24 h. Exclusion criteria: 1. Patients with NYHA class III or IV heart failure at screening; 2. Patients who have had myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or undergone cardiac surgery, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), valvular repair/replacement, or received treatment with left ventricular assist device within 3 months prior to screening; 3. Patients undergoing renal replacement therapy (RRT) at screening; 4. Patients on systemic immunosuppression at screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy. The stable maintenance therapy means treatment at least 3 months with Prednisone 10mg/day or lower (or equivalent dose of other drugs), Azathioprine 100mg/day or lower, or Mycophenolate mofetil 1000mg/day or lower (or equivalent dose of other drugs); 5. Patients with a life expectancy of less than 1 year, as judged by the investigator; 6. Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 month prior to being enrolled. Group B (patients with CKD and Hypertension) Inclusion \& Exclusion Criteria: Inclusion criteria: 1. Last documented test within 12 months prior to enrollment indicating UACR\>200 mg/g（22.6 mg/mmol）and \<5000 mg/g（565 mg/mmol）, or UPCR \>500 mg/g and \<8000 mg/g, or 24 h urine protein (quantitative) \>0.5 g/24 h and \<8 g/24 h; 2. Patients with hypertension history and Systolic Blood Pressure ≥130 mmHg at screening; Exclusion criteria: 1. Patients with NYHA class IV heart failure at screening; 2. Patients who have had stroke, transient ischemic attack (TIA), Carotid artery surgery or carotid angioplasty and stenting, acute Coronary Syndrome, or hospitalization caused by heart failure deterioration within 3 months prior to screening; 3. Patients who have known severe hepatic injury (defined as Child-Pugh class C) based on medical history; 4. Patients undergoing renal replacement therapy (RRT) within 12 weeks prior to screening; 5. Patients on systemic immunosuppression prior to screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy at least 3 months; 6. Patients with a life expectancy of less than 1 year, as judged by the investigator; 7. Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 months prior to being enrolled.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases

Contacts and locations

Locations

Research Site

Baotou, China
Research Site

Beijing, China
Research Site

Changsha, China
Research Site

Changzhou, China
Research Site

Chengdu, China
Research Site

Chongqing, China
Research Site

Dongguan, China
Research Site

Guangzhou, China
Research Site

Haikou, China
Research Site

Hefei, China
Research Site

Hengyang, China
Research Site

Huaian, China
Research Site

Jilin City, China
Research Site

Jining, China
Research Site

Nanchang, China
Research Site

Nanjing, China
Research Site

Nanning, China
Research Site

Ningbo, China
Research Site

Panjin, China
Research Site

Pingxiang, China
Research Site

Shanghai, China
Research Site

Shantou, China
Research Site

Shenzhen, China
Research Site

Taizhou, China
Research Site

Wenzhou, China
Research Site

Wuhan, China
Research Site

Wuxi, China
Research Site

Xiamen, China
Research Site

Xianyang, China
Research Site

Yantai, China
Research Site

Yibin, China
Research Site

Zhongshan, China
Research Site

Zhuzhou, China
Research Site

Zigong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.